RapidAI provides physicians clinical decision support data within minutes, and care teams the ability to streamline workflows and coordinate care throughout the patient journey.
"[We] received the highest recognition... for rapid treatment of acute stroke patients...: door to needle time within 30 minutes for at least 50% of tPA patients." — Brijesh P Mehta, M.D., Director, Memorial Neuroscience Institute
Intelligence gained from over 12 million scans continues our legacy of paving the way for a new standard of care for stroke patients, originally endorsed by the American Heart Association guidelines in 2015.
Four of 10 randomized endovascular therapy for stroke trials used RapidAI to select optimal patients for enrollment, which achieved substantially larger clinical benefits than the other trials.
With more than 320 publications producing an average impact factor of 17.1, RapidAI stroke products deliver proven benefits to hospitals in 100 countries—redefining how they care for stroke patients.
Rapid products have been extensively studied and validated in 25 clinical trials, resulting in improved clinical outcomes, new AHA guidelines and an extended treatment window of 24 hours.
Our cutting-edge AI technology helps physicians make expedient diagnoses and treatment-or-transfer decisions to improve patient outcomes and save more lives.
“We are notified of patients in outlying hospitals with positive scans or LVOs as the scan gets done so by the time the radiologist is calling the ER...we are already aware of this patient..."
Rapid clinical results and the Rapid Workflow for Stroke mobile and web apps help align stroke care teams across hospitals, saving time so patients can get the treatment they need when they need it.
"We continue to improve Door to Neuro Lab activation at our spoke hospitals with a best average time of 49 minutes in the last 6 months.”
Reports and analytics compiled from patient-journey data save hospital staff time while helping them identify trends to make more informed operational and financial decisions.
“Generated the largest return on investment for LifeBridge”
With products to fit hospitals of all sizes, the clinically validated Rapid platform uses artificial intelligence to create high quality, advanced views of the brain from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans.
The RapidAI NCCT Stroke Solution is a powerful suite of non-contrast CT (NCCT) AI modules that goes beyond triage and notification, providing clinical depth and value for faster, more accurate diagnostic decisions earlier in the stroke patient journey.
The only, premiere, FDA-approved AI-based medical device that determines suspicion of ICH and LVO based on non-contrast CT (NCCT) imaging. Rapid NCCT Stroke’s triage and notification algorithm is the first of its kind to give integrated suspicion output based on multiple stroke-related indicators, helping physicians make early and time-sensitive stroke workflow decisions with faster notification of suspected ICH or LVO.
A fully automated system that uses the latest in artificial intelligence technology to quickly triage non-contrast CT (NCCT) cases to notify physicians of possible intracranial hemorrhage (ICH) within three minutes of case receipt.
Rapid ICH and Rapid Hyperdensity use the latest in artificial intelligence technology to quickly triage non-contrast CT (NCCT) cases by immediately notifying clinicians of possible intracranial hemorrhage (ICH) and then providing identified hyperdense regions of the brain.
Rapid ASPECTS, based on the Alberta Stroke Program Early CT Score (ASPECTS) system, uses a validated machine-learning algorithm to automatically identify the ASPECTS regions of the brain and generate an ASPECT score
Rapid CTA automatically processes CT scans to quickly deliver clear CT angiography images that identify regions of asymmetry in blood vessel density for faster, more accurate patient care decisions.
In as few as three minutes, Rapid LVO helps physicians quickly identify suspected large vessel occlusions (LVOs) involving the distal internal carotid artery (ICA) or the middle cerebral artery (MCA-M1) to help speed triage decision making and facilitate better patient outcomes.
Rapid CTP enables physicians to assess salvageable brain tissue through the delivery of quantified and color-coded CT perfusions maps that identify brain regions with reduced cerebral blood flow, volume, density, and transit time.
Rapid MRI helps physicians assess salvageable brain tissue through the delivery of quantified and color-coded MR diffusion and perfusion maps that identify brain regions with reduced apparent diffusion coefficient (ADC) and transit time.
A portfolio of analytic reports presenting data about Rapid scan, treatment, and outcomes data designed to help sites and systems make more informed business decisions and save money.
Get notifications for new cases and access Rapid results using Google Chrome or Microsoft Edge on any desktop or laptop — saving you and your patients precious time.
The Rapid Mobile App gives physicians the ability to receive anywhere, anytime notifications of new cases, preview Rapid results and source files, and enable workflow communications among stroke team members via their mobile devices.
“…RAPID is unparalleled in ease of implementation and use. RAPID elevates perfusion imaging in the management of acute ischemic stroke.”
